Improving cancer immunotherapy by enhancing T cell signaling
Optimizing TCR-CD3 signaling for immunotherapy of cancer
This study is looking at ways to make cancer treatments work better by helping your immune system's T cells recognize and fight cancer cells more effectively, while also reducing side effects.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University School of Medicine NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11073098 on NIH RePORTER |
What this research studies
This research focuses on optimizing T cell receptor (TCR)-CD3 signaling to improve the effectiveness of cancer immunotherapies. By studying how T cells recognize and respond to cancer cells, the researchers aim to enhance the immune system's ability to attack tumors while minimizing side effects. The approach involves modifying specific interactions within the TCR-CD3 complex to boost T cell responses without compromising their ability to target cancer cells accurately. This could lead to more durable and effective treatments for patients with various cancers.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with cancers that have shown limited response to current immunotherapies.
Not a fit: Patients with cancers that are not amenable to T cell-based therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer immunotherapies that provide longer-lasting responses in patients.
How similar studies have performed: Previous research has shown promise in enhancing T cell responses through similar signaling pathway modifications, indicating potential for success in this approach.
Where this research is happening
New York, United States
- New York University School of Medicine — New York, United States (Active)
Researchers
- Principal investigator: Krogsgaard, Michelle — New York University School of Medicine
- Study coordinator: Krogsgaard, Michelle
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.